TWi Pharma reports data for AC-201 in Type II diabetes

TWi Pharmaceuticals Holding Inc. (Taipei, Taiwan) said twice-daily 75 mg oral AC-201 led to a significant placebo-corrected reduction in HbA1c from baseline to week 24, the primary endpoint, of 0.35% ...